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Function of FXYD Proteins, Regulators of Na,K-ATPase
Ka¨thi Geering1
In this short review, we summarize our work on the role of members of the FXYD protein
family as tissue-specific modulators of Na,K-ATPase. FXYD1 or phospholemman, mainly ex-
pressed in heart and skeletal muscle increases the apparent affinity for intracellular Na+ of Na,K-
ATPase and may thus be important for appropriate muscle contractility. FXYD2 or γ subunit and
FXYD4 or CHIF modulate the apparent affinity for Na+ of Na,K-ATPase in an opposite way,
adapted to the physiological needs of Na+ reabsorption in different segments of the renal tubule.
FXYD3 expressed in stomach, colon, and numerous tumors also modulates the transport prop-
erties of Na,K-ATPase but it has a lower specificity of association than other FXYD proteins
and an unusual membrane topology. Finally, FXYD7 is exclusively expressed in the brain and
decreases the apparent affinity for extracellular K+, which may be essential for proper neuronal
excitability.
KEY WORDS: FXYD proteins; Na,K-ATPase regulation; Na+ reabsorption; muscle contractility; neuronal
excitability.
INTRODUCTION
The ubiquitous Na,K-ATPase transports 3 Na+ out of
the cell in exchange for 2 K+ by using the energy of the hy-
drolysis of one ATP. The main task of Na,K-ATPase is to
maintain the Na+ and K+ gradients between the intra- and
extracellular milieu of animal cells, which are essential for
basic cellular homeostasis. Moreover, Na,K-ATPase is es-
sentially involved in specialized tissue functions such as
renal Na+ reabsorption, muscle contraction, and neuronal
excitability.
Na,K-ATPase is an oligomeric protein. The catalytic
α subunit, which has 10 transmembrane domains, hydrol-
yses ATP and transports the cations whereas the β subunit
acts as a molecular chaperone necessary for the correct
membrane insertion of the α subunit (Geering, 2001).
Four α and 3β isoforms exist which show tissue-specific
distribution and which can potentially form 12 different
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Na,K-ATPase isozymes with different transport properties
(Crambert et al., 2000).
In view of its important physiological role, Na,K-
ATPase expression and/or activity must be finely regu-
lated. The intracellular Na+ concentration is the rate lim-
iting factor for the activity of Na,K-ATPase and thus any
change in the intracellular Na+ concentration will affect
the transport rate of Na,K-ATPase. Moreover, hormones
and neurotransmittors determine the number of functional
Na,K-ATPase units at the cell surface either by modulating
the distribution of Na,K-pumps between the plasma mem-
brane and intracellular stores, or by controlling gene tran-
scription (Feraille and Doucet, 2001). Recently, a novel
regulatory mechanism has been elucidated which involves
tissue- and isozyme-specific interaction of Na,K-ATPase
with small membrane proteins of the FXYD protein fam-
ily (Crambert and Geering, 2003).
In mammals, the FXYD protein family con-
tains seven members (Sweadner and Rael, 2000) in-
cluding FXYD1 (or phospholemman) (Palmer et al.,
1991), FXYD2 (or the γ subunit of Na,K-ATPase)
(Forbush et al., 1978; Mercer et al., 1993), FXYD3
(or mammary tumor marker Mat-8) (Morrison et al.,
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Fig. 1. The FXYD protein family. (A) Membrane topology of FXYD
proteins with indications of the positions of conserved amono acid
residues. (B) The seven members of the FXYD protein family. Indicated
are the tissues in which FXYD proteins could be coimmunoprecipi-
tated with Na,K-ATPase and the functional effect of FXYD proteins on
Na,K-ATPase affinity for K+ and Na+ as measured after coexpression
in Xenopus oocytes. For details see text.
1995), FXYD4 (or corticosteroid hormone-induced fac-
tor CHIF) (Attali et al., 1995), FXYD5 (or related
to ion channel RIC or dysadherin) (Fu and Kamps,
1997), FXYD6 (or phosphohippolin) (Yamaguchi et al.,
2001), and FXYD7 (Be´guin et al., 2002). Moreover,
FXYD2 from Xenopus laevis (Be´guin et al., 1997) and
a phospholemman-like protein from shark (Mahmmoud
et al., 2003) have been cloned. These proteins are charac-
terized by a FXYD motif, two conserved glycine residues,
and a serine residue. Most FXYD proteins, which have
been studied so far, are type I membrane proteins expos-
ing their N-terminus to the extracytoplasmic side (Be´guin
et al., 1997, 2001, 2002; Palmer et al., 1991) (Fig. 1(A)).
FXYD1 (Palmer et al., 1991) and FXYD4 (Be´guin et al.,
2001) adopt this membrane orientation after cleavage of
a signal peptide. Several posttranslational modifications
have been identified, e.g., kinase-mediated phosphoryla-
tion in FXYD1 or phospholemman (Palmer et al., 1991)
or O-glycosylation in FXYD7 (Be´guin et al., 2002). Fi-
nally, it is interesting to note that a mutation of a conserved
glycine residue into an arginine residue in FXYD2 or the
γ subunit has been linked to cases of human hypomagne-
semia (Meij et al., 2000).
FXYD2 or the γ subunit was the first FXYD protein
that was shown to be associated with renal Na,K-ATPase
(Forbush et al., 1978), and to modulate its transport prop-
erties (Be´guin et al., 1997). During the last few years, we
and others have identified five out of seven FXYD pro-
teins as specific modulators of Na,K-ATPase. All affect
the apparent affinity for extracellular K+ of Na,K-ATPase
(Be´guin et al., 2001, 2002; Crambert et al., 2002, 2005). In
addition, FXYD1 (Crambert et al., 2002), FXYD2 (Arys-
tarkhova et al., 1999; Be´guin et al., 2001; Pu et al., 2001),
FXYD3 (Crambert et al., 2005), and FXYD4 (Be´guin
et al., 2001; Garty et al., 2002) affect the apparent affin-
ity for internal Na+ of Na,K-ATPase in a way which is
consistent with the physiological demands of the tissues
in which they are expressed.
In the following, I will summarize our recent pub-
lished work on the characterization of FXYD proteins,
their effects on the Na,K-ATPase, and the identification
of interaction sites between FXYD proteins and Na,K-
ATPase (Figs. 1 and 2).
FXYD1 (PHOSPHOLEMMAN)
FXYD1 is widely distributed with highest expres-
sion in heart and skeletal muscle (Chen et al., 1997).
FXYD1 produces chloride-activated currents (Moorman
et al., 1995) and transports the zwitterionic amino acid
taurine (Kowdley et al., 1997) after expression in Xeno-
pus oocytes or added to lipid bilayers. Moreover, it was
recently shown that FXYD1 colocalizes with Na/Ca ex-
changer and coimmunopreciptation experiments suggest
a direct interaction between the two proteins (Mirza et al.,
2004), which leads to inhibition of the Na/Ca exchanger
(Zhang et al., 2003).
We have recently shown that FXYD1 associates sta-
bly with six different Na,K-ATPase isozymes after coex-
pression in Xenopus oocytes, and with α1-β and to a lesser
extent with α2-β complexes in heart and skeletal muscles
(Crambert et al., 2002). In Xenopus oocytes, stoichiomet-
ric association of FXYD1 and Na,K-ATPase occurs post-
translationally. As assessed by voltage-clamp techniques,
association of FXYD1 with Na,K-ATPase produces a
small increase in the apparent affinity of Na,K-ATPase for
external K+ and an about twofold increase in the affinity
for internal Na+ (Crambert et al., 2002) (Fig. 1(B)). This
increase in the internal Na+ affinity of Na,K-ATPase may
be favorable in excitable tissues such as heart and skeletal
muscle to extrude efficiently increased intracellular Na+
during action potentials and to ensure appropriate muscle
contractility.
The question remains to be answered what mech-
anisms regulate the potentially multiple functions of
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FXYD1, e.g., whether phosphorylation or hormonal stim-
ulation influence the role of FXYD1 as a channel-forming
protein, as a modulator of Na/Ca exchanger, or as a regu-
lator of Na,K-ATPase.
FXYD2 (γ SUBUNIT) AND FXYD4 (CHIF)
The two spliced variants FXYD2a and FXYD2b are
mainly expressed in the medullary thick ascending limb of
the kidney (Kuster et al., 2000; Pu et al., 2001; Sweadner
and Rael, 2000) and FXYD4 is abundant in the distal colon
and the medullary collecting duct of the kidney (Shi et al.,
2001).
Our studies show that FXYD2 variants (Be´guin et al.,
1997, 2001) and FXYD4 (Be´guin et al., 2001) associate
with Na,K-ATPase α1-β complexes both after coexpres-
sion in oocytes and in the kidney. Association of FXYD2
is not necessary for the expression and activity of Na,K-
ATPase but the stability of FXYD2 itself depends on the
association with Na,K-ATPase (Be´guin et al., 1997). The
FXYD motif of FXYD2 and FXYD4 is necessary for
the stable association with Na,K-ATPase (Be´guin et al.,
2001).
Interaction of FXYD2a and FXYD2b affects slightly
the apparent affinity for extracellular K+ and Na+ and de-
creases the apparent affnity for intracellular Na+ of Na,K-
ATPase. On the other hand, interaction with FXYD4 af-
fects the apparent affinity for extracellular K+ and Na+
and increases twofold the apparent affinity for intracel-
lular Na+ (Be´guin et al., 2001) (Fig. 1(B)). Positively
charged residues in the cytoplasmic domain are impor-
tant for the functional effects of FXYD4. The differential
effects of FXYD2 and FXYD4 on the affinity for intra-
cellular Na+ of Na,K-ATPase are likely to be of physi-
ological relevance and may reflect the different roles of
Na,K-ATPase in the Na+ reabsorption process in differ-
ent segments of the renal nephron. FXYD2 is mainly ex-
pressed in the thick ascending limb, which reabsorbs up
to 40% of the filtered Na+ load. In this renal segment, a
decrease in the Na+ affinity of Na,K-ATPase by associa-
tion with FXYD2 is favorable and permits efficient extru-
sion of cellular Na+ even at high intracellular Na+ con-
centrations. In contrast, FXYD4 is exclusively expressed
in the collecting duct which is the ultimte site of elec-
trolyte conservation. In this renal segment, an increase
in the Na+ affinity of Na,K-ATPase by the association
with FXYD4 is favorable and permits efficient Na+ re-
absorption even at low intracellular Na+ concentrations.
From the effect of FXYD4 on the Na+ affinity, it can be
estimated that at low physiological intracellular Na+ con-
centrations, Na,K-ATPase associated with FXYD4 has an
about fourfold higher transport rate than Na,K-ATPase
lacking FXYD4.
FXYD3 (Mat-8)
Most recently, we have studied a fifth member of
the FXYD family namely FXYD3. FXYD3 or Mat-8,
mammary tumour marker was previously identified as
a phospholemman-like protein inducing a chloride con-
ductance when overexpressed in Xenopus laevis oocytes
(Morrison et al., 1995). FXYD3 is expressed at high lev-
els in uterus, stomach, and colon (Morrison et al., 1995).
Significantly, FXYD3 is overexpressed in human breast
cancer tumors and in tumors initiated by c-neu or v-Ha-
ras oncongenes but not in tumors initiated by the c-myc
oncogene (Morrison and Leder, 1994). Moreover, FYXD3
has been implicated in both antiproliferating (Maxwell
et al., 2003) and proliferating processes (Grzmil et al.,
2004).
Our studies revealed un uncommon membrane topol-
ogy of FXYD3. The SignalP program predicts a signal
peptide cleavage site with high probabitity in FXYD3 sim-
ilar to FXYD4. To monitor the signal petide cleavage, we
expressed FXYD3 in a reticulocyte lysate in the absence
or presence of dog pancreatic microsomes. Surprisingly,
both in the absence and presence of microsomes, the wild-
type FXYD3 migrated at a higher molecular mass than
a truncated mutant lacking 22 N-terminal amino acids.
Moreover, FXYD3 expressed in oocytes, in transfected
HEK cells or in the stomach has a similar molecular mass
than that of FXYD3 expressed in vitro. These results sug-
gest that the signal peptide of FXYD3 is not cleaved and
that in contrast to all other FXYD proteins studied, which
adopt a type I orientation, FXYD3 most likely has two
transmembrane segments (Crambert et al., 2005).
Similar to other FXYD proteins, FXYD3 associates
with Na,K-ATPase after expression in Xenopus oocytes
and does not associate with sarcoplasmic, endoplas-
mic reticulum Ca-ATPase. However, in contrast to other
FXYD proteins, FXYD3 also associates with gastric and
colonic H,K-ATPase and thus has a lower specificity.
Moreover, the processing of the β subunit of Na,K-ATPase
and H,K-ATPase from a coreglycosylated to a fully gly-
cosylated form is significantly delayed by FXYD3 sug-
gesting that FXYD3 may interfere with the ER exit of
these proteins or with the sorting pathway to the plasma
membrane (Crambert et al., 2005).
In view of the lower interaction specificity of FXYD3
with Na,K-ATPase observed in Xenopus oocytes, we
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looked whether in the stomach, where both Na,K-ATPase
and H,K-ATPase are expressed, FXYD3 is associated with
both ATPases. In stomach microsomes, FXYD3 can only
be coimmunoprecipitated with a Na,K-ATPase α subunit
antibody and not with a H,K-ATPase α subunit antibody
(Fig. 1(B)). To better understand the reason for this speci-
ficity, we investigated the localization of FXYD3 in the
gastric gland. FXYD3 is mainly expressed in cells form-
ing the upper part of the gastric gland namely in the mu-
cus cells and is absent in H,K-ATPase-containing cells,
namely the parietal cells. On the other hand, FXYD3
colocalizes with Na,K-ATPase in the mucus cells at the
basolateral membrane. Thus, the specificity of interaction
of FXYD3 with Na,K-ATPase in situ is due to the fact that
FXYD3 is not expressed in H,K-ATPase containing cells.
Finally, FXYD3 is also expressed in the apical membrane
of mucus cells suggesting that it may have other functions
in addition to its regulation of Na,K-ATPase (Crambert
et al., 2005).
Studies on the effect of FXYD3 on the Na,K-ATPase
transport properties after coexpression in Xenopus oocytes
revealed that FXYD3 increases the K1/2 value for extra-
cellular K+ over a large range of membrane potentials and
also the K1/2 value for intracellular Na+ (Crambert et al.,
2005) (Fig. 1(B)).
In conclusion, our results show that FXYD3 is able
to associate with Na,K-ATPase to modify its transport
properties similar to other FXYD proteins. However, in
addition to this shared function, FXYD3 shows some
uncommon characteristics, e.g., its untypical membrane
topology, its lower specificity, and its effect on the gly-
cosylation processing. The physiological relevance of
these characteristics remains to be determined. Further
experiments are also needed to show whether regula-
tion of the functional properties of Na,K-ATPase by
FXYD3 leading to a modification of the ionic cellular
milieu may be important for triggering or impeding cell
proliferation.
FXYD7
FXYD7 is exclusively expressed in brain both in
neurons and glial cells (Be´guin et al., 2002). Expressed
in Xenopus oocytes, FXYD7 associates with α-β1 but not
with α-β2 Na,K-ATPase isozymes whereas in the brain,
FXYD7 can only be coimmunoprecipited with α1 anti-
bodies (Be´guin et al., 2002) (Fig. 1(B)). FXYD7 con-
tains a C-terminal valine residue, which is involved in
a rapid ER export and may explain the observed post-
translational association of FXYD7 with Na,K-ATPase
(Crambert et al., 2004).
FXYD7 decreases the apparent affinity for external
K+ over a large range of membrane potentials in the ab-
sence and presence of external Na+. Moreover, the activity
of Na,K-ATPase associated with FXYD7 is more strongly
inhibited by external Na+ than that of the Na,K-ATPase
lacking FXYD7 indicating that the translocation and the
release of Na+ are also affected by FXYD7. These ef-
fects of FXYD7 are only observed for α1-β1 and α2-β1
complexes but not for α3-β1 complexes (Be´guin et al.,
2002). The two conserved glycine residues, which are on
the same side of the transmembrane helix of FXYD7, are
involved in both the association and the functional effect
of FXYD7 (Crambert et al., 2004). Finally, in contrast
to the apparent K+ affinity, FXYD7 does not produce an
effect on the affinity for intracellular Na+ (Be´guin et al.,
2002) (Fig. 1(B)). Na,K-ATPase determines the rate of
recovery of baseline external K+ during neuronal activity
and is responsible for the postactivity extracellular K+
undershoot. A Na,K-ATPase/FXYF7 complex with a low
affinity for K+ may be of physiological relevance in the
brain to ensure proper excitability of neurons and/or to
prevent an excessive K+ undershoot.
INTERACTION SITES BETWEEN Na,K-ATPase
AND FXYD PROTEINS IN THE
TRANSMEMBRANE DOMAIN
We based our analysis on the interaction sites be-
tween FXYD proteins and Na,K-ATPase on a model of the
structure of renal Na,K-ATPase (Hebert et al., 2001). In
this model, FXYD2 is supposed to be located in a pocket
made up of transmembrane domains TM9, 6, 4, and 2
of the Na,K-ATPase α subunit (Fig. 2(A)). Our analysis
revealed that one face of the TM9 helix plays a role in
the structural and functional interaction with FXYD pro-
teins (Li et al., 2004). Interestingly, we can distiguish
different domains of interaction. Leu964 and Phe967 con-
tribute to the stable interaction between the α subunit and
FXYD2, FXYD4, and FXYD7 but not to the functional
effect of these FXYD proteins on the apparent K+-affinity
of Na,K-ATPase. On the other hand, Phe956 and Glu960 do
not contribute to the stable interaction between the two
proteins but transmit the K+ effect of FXYD proteins to
Na,K-ATPase (Fig. 2(B)). In contrast to the K+ effect,
the Na+ effect of certain FXYD proteins such as FXYD4
is not mediated by Phe956 and Glu960. Significantly, a
docking model of the Na,K-ATPase/FXYD7 complex is
in very good agreement with the experimental data (Li
et al., 2004). All residues in TM9 identified in mutagen-
esis studies are involved in contacts with FXYD7. In ad-
dition, the model predicts amino acids in TM2 as contact
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Fig. 2. Structural and functional interaction sites between Na,K-ATPase
and FXYD proteins. (A) Model of the disposition of the transmem-
brane (TM) helices of the α subunit of Na,K-ATPase in a view from
the cytoplasmic side according to Hebert et al. (2001). Indicated is the
putative localization of FXYD proteins and the region in TM9 of the
α subunit which has been studied for its role in the interaction with
FXYD proteins. (B). Schematic representation of the interaction site in
TM9 of the α subunit with FXYD proteins. Indicated are amino acids
which are either involved in the stable interaction with FXYD proteins
or transmit the functional effect of FXYD proteins on the K+ affinity of
Na,K-ATPase. For details see text.
sites with FXYD7. Thus, TM9 of the Na,K-ATPase α sub-
unit contributes to the structural and functional interaction
with FXYD proteins, but other TM helices of the binding
pocket between TM9, 6, 4, and 2 or extramembraneous
interaction sites may also be involved and remain to be
determined.
CONCLUSIONS
Our data indicate that all FXYD proteins are tissue-
specific auxilary subunits of Na,K-ATPase which regulate
its activity in agreement with the physiological require-
ments of the tissue in which they are expressed. On the
other hand, much has still to be learnt on the mechanisms
that link Na,K-ATPase modulation by FXYD proteins to
physiological and pathophysiological changes of cellular
homeostasis, and to reveal the existence and the signifi-
cance of other possible functions of FXYD proteins, e.g.,
as channels or regulators of other proteins than Na,K-
ATPase.
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